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SurvivalAbstract Background: Long noncoding RNAs (lncRNAs) are a recently discovered class of tran-
scribed RNA molecules with a length of more than 200 nucleotides. Recent studies have shown that
lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) could play an impor-
tant role in carcinogenesis and cancer progression in several types of malignancies.
Objective: As little is known about the role and clinical signiﬁcance of lncRNA MALAT1 in
glioblastoma multiform (GBM) patients in Egyptian population, this study aimed to investigate
the expressions of lncRNA-MALAT1 in human GBM samples and to correlate these expressions
with the available clinicopathological features including patient survival data.
Subjects and methods: The relative expression of MALAT1 was determined in 37 human
glioblastoma formalin-ﬁxed parafﬁn embedded (FFPE) tissue samples and 10 FFPE non-
neoplastic brain tissues using quantitative reverse transcription polymerase chain reaction (qRT-
PCR) technology.
Results: The current results revealed that lncRNA MALAT1 expression was down-regulated in
all tumor specimens compared to normal tissues. A receiver operating characteristic (ROC) curve
analysis showed high diagnostic performance; area under curve (AUC) = 0.925 ± 0.038
(P< 0.001), 95% CI = 0.850–1.00, with 94.6% sensitivity, and 72.7% speciﬁcity. LowerMALAT1
expression was associated with poor prognosis; higher frequency of recurrence (P< 0.044), lower
overall survival (P< 0.005), and shorter disease-free survival (P< 0.004).-coding
urvival;
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of poor survival in glioblastoma multiformeConclusion: Taken together, we could postulate that MALAT1 might have a tumor-suppressive
function in GBM in Egyptian population and this speciﬁc type of lncRNAs may be included in the
lists of both potential prognostic biomarkers and the future therapeutic targets for glioblastomas.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glioma is by far the most common primary brain tumor asso-
ciated with poor outcome and survival [1]. It has been classi-
ﬁed into well-differentiated low grade astrocytomas (grade I–
II), anaplastic astrocytomas (grade III), and glioblastoma mul-
tiforme (GBM; grade IV) according to World Health Organi-
zation (WHO) [2]. Despite standard treatment that typically
includes neurosurgery, chemotherapy and, radiation, recent
clinical trials have reported a median survival of only 14–
16 months with a 26–33% 2-year survival rate [3]. It has been
suggested that the WHO criteria to predict the patient clinical
outcomes may not be sufﬁcient alone to estimate patient prog-
nosis [4]. More recently, improved understanding of glioma
molecular genetics has led to identifying new potential
biomarkers for early diagnosis, prognosis prediction, and
novel therapeutic targets [5].
Long noncoding RNAs (lncRNAs) are a recently discov-
ered class of transcribed RNA molecules with a length of more
than 200 nucleotides. Similar to protein-coding genes, they
have promoter structure, and are transcribed by RNA poly-
merase II, polyadenylated, and subjected to splicing. However,
unlike mRNA, they do not encode proteins [6]. LncRNAs are
thought to be important regulators of gene expression at tran-
scription, translation and epigenetic levels [7,8]. An accumulat-
ing number of evidences suggested that lncRNAs may have
critical roles in a wide range of biological processes [9]. Screen-
ing lncRNAs expression proﬁle in glioma has revealed a signif-
icant contribution to pathogenesis [10], development and
progression [11–13] by regulating cell growth and metastasis;
indicating that lncRNAs play signiﬁcant roles in glioma
tumorigenesis [14].
The functional lncRNA-MALAT1 (metastasis-associated
lung adenocarcinoma transcript 1); encoded by MALAT1
gene, which is located at chromosome 11q13.1. [15], and also
known as nuclear-enriched abundant transcript 2 (NEAT2),
was one of the ﬁrst lncRNAs found to have a pathogenic role
[16] and it has been linked to various cancers besides lung ade-
nocarcinoma [17]. Its expression proﬁle has been found to be
dysregulated and correlated with clinical parameters and prog-
nosis in several types of human cancer, such as hepatocellular
carcinoma [18], osteosarcoma [19], lung cancer [20], bladder
cancer [21], and glioblastoma multiforme [22].
As there are no previous studies, up to the researchers’
knowledge, on the expression of this type of lncRNAs in
GBM patients among the Arab population, this study for
the ﬁrst time will aim to determine the expression levels of
MALAT1 in a sample of GBM patients and correlate these
expressions with the available clinicopathological features
including patient survival data in a sample of Egyptian
population.et al., Long noncoding RNA metastasis-
in Egyptian patients, Egypt J Med Hum2. Subjects and methods
2.1. Patients and tissue samples
The present study included 37 formalin-ﬁxed parafﬁn embed-
ded (FFPE) glioblastoma samples, fulﬁlling the WHO criteria
of GBM and 10 FFPE non-neoplastic brain tissue specimens.
GBM patient samples (9 females and 28 males, aged 35 to
60 years old) have been assessed retrospectively from the
archive of the Pathology Departments, Mansoura University
Hospitals and Suez Canal University Hospitals, Egypt, from
2010 to 2013. Detailed patients’ data were retrieved from their
medical follow up records. All patients had GBM (i.e. grade
IV), undergone surgical removal and post-operative irradia-
tion, and followed for more than 3 years. The work has been
carried out in accordance with the code of ethics of the world
medical association (Declaration of Helsinki) for experiments
on humans. All patients gave written informed consent, except
for deceased individuals or patients who provided archived tis-
sue samples and can’t be traced.
2.2. Total RNA extraction
Following deparafﬁnization in xylene and washing with alco-
hol, the total RNA was extracted from tumor and control
FFPE tissue sections (4–5 lm) collected in sterile eppendorf
tubes. Qiagen RNeasy FFPE Kit (Cat. No. 73504, Qiagen,
Hilden, Germany) has been used following the protocol sup-
plied by the manufacturer. Extracted total RNA concentration
and purity at the absorbance ratio 260/280 nm were deter-
mined by NanoDrop ND-1000 spectrophotometer (Nano-
Drop Tech., Inc. Wilmington, DE, USA). In addition, RNA
degradation and contamination were assessed by 1.5% agarose
gel electrophoresis.
2.3. Reverse transcription
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, P/N 4368814) was used for reverse transcription
(RT) reaction. For each 20 ll RT reaction, 10 ll (10 ng)
RNA sample was combined with 10 ll of 2 RT reaction
mix containing 2 ll of 10 RT Buffer, 0.8 ll of 25 dNTP
Mix (100 mM), 2 ll of 10 RT random primers, 1 ll of
MultiScribeTM Reverse Transcriptase, 1 ll of RNase inhibi-
tor, and 3.2 ll of nuclease-free water. RT was carried out
in a T-Professional Basic, Biometra PCR System (Biometra,
Goettingen, Germeny) at 25 C for 10 min, followed by
37 C for 120 min, and ﬁnally 85 C for 5 min, then held
at 4 C. Appropriate negative controls were included in each
experiment.associated lung adenocarcinoma transcript 1 (MALAT1): A molecular predictor
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.003
LncRNA-MALAT1 and GBM 32.4. Gene expression analysis
Real-time polymerase chain reaction (PCR) was performed in
accordance with the Minimum Information for Publication of
Quantitative Real-Time PCR Experiments (MIQE) guidelines.
Expression of MALAT1 and the endogenous control
TBP (Tata binding protein) were quantiﬁed using TaqMan
assays (Applied Biosystems, assay ID Hs00273907_s1, and
Hs00427620_m1, respectively) and Taqman Universal PCR
master mix II, No UNG (2) (Applied Biosystems, P/N
4440043). Apart for TBP, none of the other conventionally
used housekeeping genes in GBM studies, were found to be
suitable as they showed variation in RNA expression [23].
Hence, TBP expression was used for normalization of qPCR
data in the current work. The PCR reactions were carried
out in a ﬁnal volume of 20 ll, including 1.33 ll RT product,
10 ll 2  TaqMan Universal PCR Master Mix, 1 ll Taq-
Man assays. All reactions included a non-template control
(with water instead of cDNA), and a no-reverse transcriptase
control. The PCR was performed on StepOneTM Real-Time
PCR System (Applied Biosystems) as follows: 95 C for
10 min followed by 40 cycles of 92 C for 15 s and 60 C for
1 min.
2.5. Statistical analysis
Statistical Package for the Social Sciences (SPSS) for Windows
software (version 20.0) was used for statistical graphics and
analyses. The following parameters were considered besides
the expression values of theMALAT1 analyzed: age at diagno-
sis, gender and tumor site. Categorical variables were com-
pared using the chi-square (v2) or Fisher’s exact tests where
appropriate, while Student’s t test or One way ANOVA were
used to compare continuous variables between two groups or
more than two groups, respectively in case the data distribu-
tion was concordant with normal distribution (Shapiro–Wilk
test) and after checking variance homogeneity (Levene’s test).
If the data did not meet the criteria mentioned above, the non-Table 1 Baseline patient characteristics (n= 37) and survival.
Mean ± SD or
Number (%)
OS (mo)
Age (years) 51.5 ± 5.9
Age, categories
35- 16 (43.2) 17.3 ± 7.08
50- 21 (56.8) 13.9 ± 2.25
Gender
Female 9 (24.3) 18.5 ± 6.9
Male 28 (75.7) 14.3 ± 4.13
Tumor site
Frontal 18 (48.6) 14.4 ± 5.09
Fronto-temporal 4 (10.8) 19.0 ± 3.46
Parietal 1 (2.7) 11.0
Temporo-parietal 14 (37.8) 19.5 ± 5.52
Recurrence
Non-recurrent 30 (81.1) 15.5 ± 5.25
Recurrent 7 (18.9) 15.0 ± 5.22
OS, overall survival; DFS, disease-free survival; mo, months. Student’s t
* Statistically signiﬁcant, P< 0.05.
Please cite this article in press as: Fawzy MS et al., Long noncoding RNA metastasis-
of poor survival in glioblastoma multiforme in Egyptian patients, Egypt J Med Humparametric Mann–Whitney-U test or Kruskal–Wallis tests
were used for comparison between groups with subsequent
Bonferroni’s post hoc test for multiple testing. The receiver
operating characteristic (ROC) curves were derived and area-
under-the curve (AUC) analysis performed to get the best cut-
off value of MALAT1 for discriminating GBM patients from
controls. P-values < 0.05 were considered statistically signiﬁ-
cant. Disease-free survival is deﬁned as the time between diag-
nosis of disease and recurrence or distant metastasis. Overall
survival is deﬁned as time from diagnosis of disease to death
of patients with brain cancer [24]. Median follow-up time
was computed by the Kaplan–Meier method. For analysis of
disease-free and overall survival, frontal and fronto-temporal
tumors were combined for comparison with those with parietal
and temporo-parietal. Log rank (Mantel–Cox) was used for
survival curves comparison. The fold change of MALAT1
expression was calculated using Livak’s method based on the
threshold cycle (CT) value with the following equation: relative
quantity = 2DDCT [25].
3. Results
3.1. Baseline characteristics of the study population
The main patient characteristics have been summarized in
Table 1. In addition, the mean ± SD of the GBM patients
overall survival (OS) and disease-free survival (DFS) were
15.4 ± 5.17 months and 14.7 ± 5.34 months with a range of
(8–27) and (6–27) months, respectively. Twenty three patients
(62.2%) showed short (61 year) disease free survival (DFS)
and only 12 (32.4%) showed a higher overall survival rate
(>1 year). As shown in Table 1, male gender was signiﬁcantly
associated with shorter DFS than females (P< 0.04).
3.2. Expression of MALAT1 in glioblastoma multiform
Compared with normal brain tissues, all GBM patients
showed low expression levels of lncRNA MALAT1P
value
DFS (mo) P
value
0.241 17.0 ± 6.89 0.123
13.09 ± 2.98
0.086 18.5 ± 6.9 0.040*
13.5 ± 4.20
0.179 13.5 ± 5.14 0.133
19.0 ± 3.46
11.0
15.4 ± 5.72
0.719 15.3 ± 5.26 0.259
12.4 ± 5.47
and ANOVA tests were used.
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Figure 1 LncRNA-MALAT1 expression levels in glioblastoma.
Data are represented as medians. The box deﬁnes upper and lower
quartiles (25% and 75%, respectively) and the error bars indicate
upper and lower adjacent limits. Mann–Whitney U test was used;
*Statistically signiﬁcant.
Area Std. Error Asymptotic Sig.
Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
0.925 0.038 .000 0.850 1.000
Figure 2 Receivers operating characteristic curve of MALAT1.
AUC: area under curve; CI: conﬁdence interval; SE, standard
error; SEN, sensitivity; SP, speciﬁcity.
4 M.S. Fawzy et al.(P< 0.001, Fig. 1) with a median expression value (quartile)
= 0.015 (0.001–0.086).
3.3. ROC curve analysis
Relative expression levels were used to determine MALAT1
sensitivity and speciﬁcity at the cutoff fold change value for
discriminating GBM patients from controls. The curve showed
high diagnostic performance with an AUC= 0.925 ± 0.038
(P< 0.001), 95% CI = 0.850–1.00, with 94.6% sensitivity
and 72.7% speciﬁcity (Fig. 2).
3.4. LncRNA MALAT1 relative expression and
clinicopathological features in GBM patients
Median MALAT1 relative expression was not associated sig-
niﬁcantly with age (<50 vs. P50, P= 0.387) or gender
(females vs. males, P= 0.196), however fronto-temporal brain
tissue samples showed a signiﬁcant lower expression in com-
parison to other sites, (P= 0.025); Fig. 3. Lower MALAT1
expression, in addition, was associated with poor prognosis;
higher frequency of recurrence, lower overall survival, and
shorter disease-free survival (Fig. 3).
As summarized in Table 2, MALAT1 expression was
directly correlated with shorted overall survival (r= 0.359,
P= 0.029) and disease-free survival (r= 0.361, P= 0.028)
and was inversely correlated with recurrence (r= 0.334,
P= 0.044).
3.5. MALAT1 expression and survival of patients with different
clinical variables
To explore the prognostic value of the lncRNA-MALAT1
expression in GBM patients, Kaplan–Meier analysis with the
log-rank test was used in comparing survival of patients with
different clinical variables (Fig. 4). Poor survival has been
shown in older patients [median (95% CI); 14 (12.5–15.4)Please cite this article in press as: Fawzy MS et al., Long noncoding RNA metastasis-
of poor survival in glioblastoma multiforme in Egyptian patients, Egypt J Med Humand 16 (8.81–23.1) in patients P50 year-old and <50 year-
old, respectively] and among males [median (95% CI); 14
(12.2–15.7) and 22 (13.6–30.3) in males and females, respec-
tively]. Otherwise, there were no signiﬁcant differences of
lncRNA MALAT1 expressions and survival of patients
regarding the tumor location or recurrence rate (Fig. 4).
4. Discussion
Human transcriptome analysis has been revealed that the
majority of human genome transcripts are non-coding RNAs,
including lncRNAs that previously were considered as tran-
scriptional noises [26]. However, an accumulating number of
evidences have revealed that lncRNAs could have important
functions and may interact with a broad range of RNA mole-
cules through competitively binding with miRNAs, suggesting
their vital roles in a wide range of biological processes and
human diseases [27]. More speciﬁcally, they have been found
to be involved in brain development and in the pathogenesis
of gliomas, and could serve as novel biomarkers for early diag-
nosis, prediction of prognosis, and therapeutic targets in glio-
mas [28,29].
The lncRNA MALAT1 gene produces a highly abundant
and ubiquitously expressed transcript of >8000 nucleotides
that is retained in the nucleus where it is thought to form
molecular scaffolds for ribonucleoprotein complexes [30].
MALAT1 was found to act as decoys that bind to and inter-
fere with the function of other RNAs or proteins (e.g. miR-
NAs, transcription factors, or RNA-binding proteins),associated lung adenocarcinoma transcript 1 (MALAT1): A molecular predictor
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.003
Figure 3 LncRNA MALAT1 relative expression and clinicopathological features in GBM patients. Data are represented as medians.
The box deﬁnes upper and lower quartiles (25% and 75%, respectively) and the error bars indicate upper and lower adjacent limits. *N.B.
In posthoc test parietal tumor group was merged with tempero-parietal one as test could not be performed by single sample.
LncRNA-MALAT1 and GBM 5especially those involved in cell cycle regulation, cell migration,
and cancer metastasis [31].
Initially, MALAT1 was identiﬁed by Ji and co-workers in
(2003) [32], through subtractive hybridization in a screen for
genes associated with metastasis in non-small cell lung cancer.
Subsequently, several studies have associated MALAT1
expression with various cancers and metastasis [33–35]. In
the current study, MALAT1 showed signiﬁcant lower expres-
sion levels in all GBM tissues compared with normal brain tis-
sues. This is consistent with a recent study ﬁnding conductedPlease cite this article in press as: Fawzy MS et al., Long noncoding RNA metastasis-
of poor survival in glioblastoma multiforme in Egyptian patients, Egypt J Med Humby Han et al. [22] who found that lncRNA MALAT1 could
have a tumor-suppressive function in glioma. This inhibitory
effect could be due to suppression of both growth and cell
invasion. At the molecular level, they suggested that this could
be mediated via regulation of the ERK/MAPK (extracellular
signal-regulated kinase/mitogen-activated protein kinase)
pathway and expression of MMP2 (matrix metalloproteinase
2). The ERK/MAPK pathway is one of the most important
signal transduction pathways, and MALAT1 upregulation in
glioma cells inhibits the growth and invasion of tumor byassociated lung adenocarcinoma transcript 1 (MALAT1): A molecular predictor
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.003
Table 2 Spearman’s rho correlation analysis between brain
tissue MALAT1 relative expression and the clinicopathological
features in GBM patients (n= 37).
Correlation coeﬃcient P
value
Age 0.104 0.539
Gender 0.142 0.402
Tumor site 0.050 0.768
OS 0.359 0.029*
DFS 0.361 0.028*
Recurrence 0.334 0.044*
OS, overall survival; DFS, disease-free survival.
* Statistically signiﬁcant, P< 0.05.
Figure 4 Kaplan–Meier curves and the log-rank (Mantel–Cox) tes
variables. Cum. Cumulative; mo, months.
6 M.S. Fawzy et al.
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of poor survival in glioblastoma multiforme in Egyptian patients, Egypt J Med Humreducing the phosphorylated ERK1/2 expression rather than
affecting the total ERK1/2, leading to inactivation of this sig-
naling cascade [22]. In earlier studies, it has been proved that
knockout of MALAT1 in lung cancer cells could signiﬁcantly
reduce the expression of several metastasis-related genes,
including Glypican 6 (GPC6) [36] and C-X-C motif chemokine
5 (CXCL5) [37], leading to MAPK pathway inactivation.
Hence GPC6 or CXCL5 expression down-regulation could
be one of the underlying mechanisms by whichMALAT1inac-
tivate ERK/MAPK pathway in glioma which require further
future validation.
In addition, Bernard et al. [38] have found that MALAT1
expression in B-cell malignancies was decreased compared
with solid tumors. Another study demonstrated signiﬁcantly
lower MALAT1 expression levels in the plasma of multiplet for comparison of the patients’ survival with different clinical
associated lung adenocarcinoma transcript 1 (MALAT1): A molecular predictor
Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.003
LncRNA-MALAT1 and GBM 7myeloma patients [39]. The results of the present study, how-
ever, were a little different from others. It has been found that
MALAT1 expression was increased in glioma tissues compared
with paired adjacent brain normal tissues by Ma et al. [14].
MALAT1 was shown, in addition, to act as oncogene in sev-
eral types of human cancer, such as lung cancer [40], breast
cancer [41], cervical cancer [42], bladder urothelial carcinoma
[21], gastric cancer [43], colorectal cancer (CRC) [44], hepato-
cellular carcinoma [34], pancreatic duct adenocarcinoma [45]
and melanoma [46]. However, MALAT1 was downregulated
in the cell culture, with the cells exhibiting high metastatic
potential for ovarian cancer metastasis [47]. This discrepancy
of results among some studies and ours could be due to the fact
that MALAT1 function may vary with various cancer types
and context; the same gene may play opposite roles in different
cancer types or in different stages of cancer progression [48].
Additionally, emerging evidence has suggested that lncRNAs
can potentially interact with other classes of non-coding RNAs
including miRNAs [49], or are regulated by transcription fac-
tors [50], indicating that lncRNAs may have regulatory roles in
a wide range of cellular processes at various levels. In addition,
the recent molecular sub-classiﬁcation of GBM includes IDH1
(isocitrate dehydrogenase 1) mutation, p53 mutation, EGFR
(epidermal growth factor receptor) ampliﬁcation and MGMT
(O-6-methylguanine-DNA methyltransferase) promoter
methylation status, all of which have proved to be partly asso-
ciated and are useful in clinical practice [13]. Their aberration
may result in signiﬁcant epigenetic changes, including DNA
methylation level, mRNA expression level [51], and lncRNA
expression level [52]. Therefore, it is recommended to investi-
gate whether there are some associations between MALAT1
signature and these well-recognized genetic biomarkers by an
intriguing multi-dimension analysis that can give useful expla-
nations for the potential result discrepancies in GBM molecu-
lar research.
In the present study, we further found that lower
MALAT1 expression was associated with poor prognosis
(i.e. higher frequency of recurrence, lower overall survival
and shorter disease-free survival). Several reports indicate
that MALAT1 contributes to the complex molecular mecha-
nisms involved in the control of cell growth, differentiation
and motility that could predict the overall prognosis and sur-
vival [21]. For example, the expression of MALAT1 was asso-
ciated with prostate cancer progression and prognosis [53],
GBM survival [13], tumor progression and survival in lung,
liver and breast cancer [54], invasion and metastasis of
CRC cells [55], proliferation and metastasis of gallbladder
cancer cells [56] and tumor recurrence of hepatocellular carci-
noma after liver transplantation [57]. All these ﬁndings indi-
cate that lncRNA MALAT-1 could be considered as an
important novel candidate for future therapeutic intervention.
However, the applicability and epigenetic regulation of
MALAT-1 targeted strategies for the clinical treatment of
GBM requires additional studies.5. Conclusion
In summary, the current study does conﬁrm the lncRNA
MALAT1 association with the glioblastoma and its potential
role as prognostic biomarker. The study was limited by the rel-
atively small sample size, and the fact that all patients werePlease cite this article in press as: Fawzy MS et al., Long noncoding RNA metastasis-
of poor survival in glioblastoma multiforme in Egyptian patients, Egypt J Med Humgrade IV gliomas. We recommend further studies of a larger
scale with different glioma grades, to explore the correlation
of MALAT1 expression with different WHO grades and to
conﬁrm its possible role as prognostic biomarker. Further
functional investigations of this type of lncRNAs on tumor cell
lines and xenograft models may increase our outstanding of its
detailed molecular roles in GBM pathogenesis and progress.
Hence, this may be an interesting target for future therapeutic
interventions in GBM patients.
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